LIVE EVENT: The U.S. healthcare law rollout: Where do we stand?
WASHINGTON - The U.S. Supreme Court on Monday left intact a $142 million jury verdict against Pfizer Inc over the marketing of the epilepsy drug Neurontin.
TEL AVIV - Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities (NTEs) could generate revenue of $1 billion to $1.5 billion by 2018.
NEW YORK (Reuters Health) - Every hour, on average, a child ends up in a U.S. emergency room with an injury associated with a high chair, according to a new study. And the risk seems to be rising.
NEW YORK (Reuters Health) - Regular exercise can help people with dementia think a little more clearly, and care for themselves a bit more, a new study finds.
NEW YORK - Merck & Co Inc said on Monday that it was prepared to pay $27.7 million to settle lawsuits by hundreds of people who sued the company over allegations that its osteoporosis drug Fosamax caused bones in the jaw to deteriorate.
COPENHAGEN - Novo Nordisk received European Union marketing authorization for its hemophilia drug NovoEight on November 13 2013, the Danish pharmaceutical company said on Monday.
NEW YORK (Reuters Health) - Girls who start puberty early may be at particular risk for problem behaviors as teenagers, a new study suggests.
- An advisory panel of medical experts on Monday voted to recommend that U.S. health regulators approve an experimental drug for ulcerative colitis and Crohn's disease developed by Takeda Pharmaceutical Co.
- Acura Pharmaceuticals Inc said the U.S. Food and Drug Administration agreed to review the results of a failed mid-stage trial of a painkiller made with the company's technology designed to deter abuse.
- U.S. Food and Drug Administration staff reviewing data on Boston Scientific Corp's novel anti-stroke device highlighted the implant's failure to meet a key goal for effectiveness in a recent study but said on Monday that other data must be weighed in deciding whether it should be approved.
On Wednesday, December 4 at 10:30 a.m. watch live as experts assess where the U.S. stands in the healthcare law rollout and the resulting health policy implications. Presented by the forum at Harvard School of Public Health in collaboration with Reuters. Live Coverage